{
    "2020-01-13": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "earnings estimates",
                        "beat"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "New Study Could Clear Johnson & Johnson on Talc, but Is It a Buy Signal?",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "talc",
                        "study",
                        "buy signal"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Glaxo Files Marketing Application for Fostemsavir in Europe",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "marketing application",
                        "Fostemsavir",
                        "Europe"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "The Zacks Analyst Blog Highlights: JPMorgan Chase, Johnson & Johnson, American Express Company, NIKE and Apple",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "JPMorgan Chase",
                        "Johnson & Johnson",
                        "American Express",
                        "NIKE",
                        "Apple"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare",
                        "consumer goods",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?",
                "features": {
                    "keywords": [
                        "Invesco",
                        "biotechnology",
                        "genome",
                        "ETF",
                        "PBE"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "genomics"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}